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Atrial fibrillation is the most commonly sustained arrhythmia in man. While it aﬀects millions of patients worldwide, its incidence
will markedly increase with an aging population. Primary goals of AF therapy are to (1) reduce embolic complications, particularly
stroke, (2) alleviate symptoms, and (3) prevent long-term heart remodelling. These have been proven to be a challenge as there are
major limitations in our knowledge of the pathological and electrophysiological mechanisms underlying AF. Although advances
continue to be made in the medical management of this condition, pharmacotherapy is often unsuccessful. Because of the high
recurrence rate of AF despite antiarrhythmic drug therapy for maintenance of sinus rhythm and the adverse eﬀects of these drugs,
there has been growing interest in nonpharmacological strategies. Surgery for treatment of AF has been around for some time.
The Cox-Maze procedure is the gold standard for the surgical treatment of atrial fibrillation and has more than 90% success in
eliminating atrial fibrillation. Although the cut and sew maze is very eﬀective, it has been superseded by newer operations that rely
on alternate energy sources to create lines of conduction block. In addition, the evolution of improved ablation technology and
instrumentation has facilitated the development of minimally invasive approaches. In this paper, the rationale for surgical ablation
for atrial fibrillation and the diﬀerent surgical techniques that were developed will be explored. In addition, it will detail the new
approaches to surgical ablation of atrial fibrillation that employ alternate energy sources.
1. Introduction
Atrial fibrillation (AF) is the most common arrhythmia
encountered in clinical practice. The overall prevalence of AF
in the population ranges between 1 and 2%. The relationship
between AF and age is strong. The prevalence doubles with
each decade of age, reaching almost 9% at the age of 80–89
years [1, 2]. This can be an underestimate of the real number
as it overlooks the undetected asymptomatic AF cases and
paroxysmal AF.
Although atrial fibrillation can be considered an innocu-
ous arrhythmia, it is associated with serious morbidity and
mortality [3]. First, it increases the risk of thromboembolism
and stroke, as a result of blood stasis in the left atrium. It has
been estimated that AF results in three- to five-fold increase
in stroke risk [4]. Second, the irregularly irregular heart beat
leads to symptoms palpitations, shortness of breath, anxiety,
and reduced exercise tolerance in the patient. Third, atrial
fibrillation leads to a number of cardiac and hemodynamic
changes including a reduced myocardial systolic function
and tachycardia-induced cardiomyopathy [5, 6].
In addition to the clinical morbidity and mortality of
AF, it imposes a huge burden on the economy. Stewart and
colleagues looked at the cost that AF imposes on health and
social services in the UK in 1995 [7]. AF accounted for 0.62%
of the UK National Health Service (NHS) expenditure,
which is equivalent to £244 million. Hospitalization and
drug prescriptions accounted for 50% and 20% of this
expenditure respectively. The expenditure is expected to rise
as the incidence of AF continues to rise due to the increase of
the number of people over the age of 80 years. Thus, AF is an
extremely expensive public health problem.
Given the great impact of atrial fibrillation on health
resources and patients’ welfare, several pharmacological and
surgical therapies have been developed over the years. The
purpose of this review is to review the rationale for surgical
ablation of atrial fibrillation and describe the diﬀerent
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approaches and procedures used in the ablation of atrial fi-
brillation in cardiac surgery patients.
2. Rationale for Surgical Ablation
AF is present in up to 50% of patients undergoing mitral
valve surgery and in 1% to 6% of patients presenting for
coronary artery bypass grafting (CABG) or aortic valve
surgery [8–11]. Atrial fibrillation is strongly associated with
mitral valve dysfunction, hence most studies focus on
patients who havemitral valve dysfunction. In those patients,
atrial fibrillation is a marker of advanced cardiovascular
disease and is associated with a more severe left ventricular
dysfunction and a greater left atrial enlargement [11–13].
AF onset can be considered a relative indication for
mitral valve surgery in those who have mitral valve dysfunc-
tion [9]. However, mitral valve surgery alone does not revert
AF back into sinus rhythm [14, 15]. In most instances mitral
valve surgery alone does not cure AF. When the duration
of AF preoperatively is longer than six months, the risk of
remaining in AF is 70–80%. In contrast, when the duration
of preoperative AF is less than three months, particularly if
it is paroxysmal, there is an 80% cure rate after mitral valve
surgery [12, 14, 16]. Therefore, ablation should be added to
the mitral valve procedure in any patient with AF greater
than six months duration or in any patient with AF that is
not paroxysmal.
3. Pathophysiology of Atrial Fibrillation
There is general agreement that AF requires a trigger for
its initiation and a substrate for its maintenance. Triggers
include atrial ectopic foci, changes in atrial wall tension, and
alteration in autonomic tone [17–19]. The substrate is an
atrial abnormality, frequently inflammation or fibrosis, and
it causes electrical dysfunction that favours development of
AF.
These substrates and triggers have been localized ana-
tomically to the pulmonary veins and the left atrium [20].
Themechanism underlying the pulmonary vein ectopy is still
under investigation. After triggers propagate into the atrial
myocardium, fibrillation is maintained by continuation of
these trigger beats with breakdown of conduction or by
intra-atrial reentrant processes.
Our understanding of AF initiation and maintenance
stems from previous experimentally founded theories that
address the genesis of AF. One theory considers AF to be
a manifestation of one or more reentry circuits (multiple-
wavelet theory) or reentrant rotors involving the atrial
surface [21]. The second theory postulates AF to be the result
of fibrillatory conduction throughout the atria originating
from a rapid discharge from one or several foci (focal theory)
[22]. Both mechanisms are relevant to the clinical spectrum
of AF.
The clinical classification of AF is helpful inmanagement.
Chronic AF can be classified into three subtypes: paroxysmal,
persistent, and permanent [23]. Paroxysmal AF is defined as
episodes that start and stop by themselves, generally lasting
less than 24 hours but sometimes lasting up to 7 days.
Persistent AF is defined as episodes lasting more than 7
days or that require termination, either pharmacologically
or electrically. Permanent AF is defined as longstanding
continuous episodes, where repeated attempts to terminate
have either failed or not tried.
Cardiac remodelling (electrical, contractile, and struc-
tural) is another important part of the pathophysiology of
AF. It plays a role in determining whether AF is persistent
or permanent. There has been an explosion of research into
atrial remodelling during AF and the converse process of
“reverse remodeling” [24, 25].
4. Surgical Treatment Options
The development of new surgical approaches to AF has
been predicated upon two factors: understanding that the
pulmonary veins and left atrium are critical to the initiation
and maintenance of AF and development of ablation tools
that use alternate energy sources to facilitate rapid and safe
creation of lines of conduction block under direct vision.
Surgical therapy ranges from simple procedures such as
removal or plication of the left atrial appendage to reduce the
risk of thromboembolic complications [26–28] to a variety of
procedures aimed at preventing the recurrence of AF.
4.1. Historical Background before the Cox Maze
4.1.1. Left Atrial Isolation. In 1980, Williams and colleagues
developed the left atrial isolation procedure by using animal
models [29]. This procedure isolated the left atrium elec-
trically from the remainder of the heart without disrupting
normal conduction. This was successful in isolating AF to the
left atrium and restoring the remainder of the heart to sinus
rhythm.
The left atrial isolation has been applied clinically by
Graﬃgna and associates [30] to a hundred patients with
chronic AF and mitral valve disease. They showed that sinus
rhythm has been restored in 72% of those patients, with
a mean follow up of 14.6 months. However, the obvious
shortcoming of this approach is continued fibrillation of
the left atrium and its uncertain impact on the risk of
thromboembolism.
4.2. The Corridor Procedure. In 1985, Guiraudon and
coworkers [31] introduced the corridor procedure for AF,
creating an isolated strip of muscle which links the sinoatrial
and AV nodes (Figure 1), thus driving ventricle rate via
the AV node-His bundle complex. This approach failed to
achieve sinus rhythm in a significant number of cases. In
addition, atrial areas outside the narrow right atrial corridor
continued to fibrillate with persistent loss of atrial transport
function and persistent risk of thromboembolism.
4.3. The Cox Maze. All the above-mentioned procedures fall
short of the ideal, which is the cure of the arrhythmia and
resolution of its principle adverse consequences (thrombo-
embolism). The Cox-Maze III operation or the Maze proce-
dure is the gold standard for surgical treatment of AF. In fact,
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Figure 1: The Corridor Procedure designed by Guiraudon in 1985. Arrow show the direction of flow of electrical current. (SN: SA node, PV:
pulmonary veins, AVN: atriventricular node, SVC: superior vena cava, IVC: inferior vena cava, LAA: left atrial appendage, and RAA: right
atrial appendage).
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Figure 2: The Cox-Maze III lesion pattern described by James Cox in 1991 with cut and sew technique. Arrows show the direction of
electrical current flow from the SA node to the atrioventricular node. (SN: SA node, PV: pulmonary veins, AVN: atriventricular node, SVC:
superior vena cava, IVC: inferior vena cava, LAA: left atrial appendage, and RAA: right atrial appendage).
it is the most eﬀective curative therapy for AF yet devised
[32–34].
In 1991, Jimmy Cox described the Maze procedure for
the surgical cardioversion of AF. Cox et al. designed the
procedure based on experimental and clinical evidence con-
cerning the pathophysiology of AF. To improve results and
simplify the operation, they modified the procedure twice,
culminating in the Cox-Maze III. In the Maze procedure,
incisions are made strategically to interrupt the multiple
macroreentrant circuits and direct the sinus impulse from
the sinoatrial node to the atrioventricular node along a
specified route (Figure 2). The Maze procedure includes
encircling and isolating the pulmonary veins and excising
the left and right atrial appendages. Although the Maze
procedure may be performed with minimal invasiveness
through a small chest wall incision, the operation requires
cardiopulmonary bypass and cardiac arrest. In experienced
hands, the Maze procedure requires 45 to 60 minutes of
cardiopulmonary bypass and cardiac arrest. The operation
may be performed alone or in conjunction with other cardiac
surgical procedures, such as mitral valve surgery or coronary
bypass grafting.
Cox et al. [35] have reported the largest series of patients
undergoing the Maze III procedure. Among 118 patients,
operative mortality was 2%. AF was cured in 93% of patients
at 8.5 years of followup, and only 2% of patients required
long-term postoperative antiarrhythmic medication.
The postoperative success was unaﬀected by presence
of mitral valve disease, left atrial size, and type of AF
(paroxysmal, persistent, or permanent). However, the atrial
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fibrillatory wave and left atrial diameter were independent
predictors of sinus rhythm restoration after the maze
procedure in patients with chronic atrial fibrillation and
organic heart disease [36].
Temporary postoperative AF and atrial arrhythmias were
common, occurring in 38% of patients. This problem was
attributed to a shortened atrial refractory period; most
importantly, postoperative AF was temporary and did not
diminish long-term results. Fifteen percent (15%) of patients
required new pacemakers postoperatively. This was a result
of the underlying sinus node dysfunction rather than the
Maze procedure itself. In spite of multiple right and left
atrial incisions, the right atrial transport function was
demonstrated in 98% of patients, and the left atrial transport
function was demonstrated in 93% of patients. Furthermore,
the Maze procedure virtually eliminated the risk of stroke
or other thromboembolism [37]. Other medical centres
reproduced these excellent results that confirm the safety of
the Maze procedure and its eﬃcacy at restoring sinus rhythm
leading to the virtual elimination of late strokes. In spite of
these excellent results, theMaze procedure has been relatively
underused, and even in patients requiring cardiac surgery
for other reasons. The perceived surgical complexity and
magnitude of the operation can account for these trends.
4.4. New Approaches for Surgical AF Ablation. In an attempt
to decrease the ischemic time and the on-pump time, the
Cox-Maze III has evolved to a procedure that uses the
latest ablation technology instead of the traditional “cut and
sew” method to achieve the designated areas of conduction
block. The main techniques use thermal energy to create the
desired electrical barriers. These include microwave, bipolar
radiofrequency, laser, and cryotherapy. The new techniques
appear to be less time consuming and less technically de-
manding.
Microwave energy has been used to create transmural
lesions on the arrested heart, but transmurality is inconsis-
tently achieved. In a prospective randomized trial, Schuetz
and colleagues [38] used a combination of microwave
ablation and atrial size reduction to restore sinus rhythm in
80% of patients presenting with permanent atrial fibrillation.
In another study, microwave and unipolar radiofrequency
produced equivalent results (80% freedom fromAF at 1 year)
when used to create the Cox-Maze III lesion set [39].
The most extensive experience has been with dry
unipolar radiofrequency devices. Analysing 16 studies that
employed this method for ablation, Khargi and colleagues
[40] found that AF has been eliminated in an average of 78%
of patients with permanent AF. The success rate ranged from
42 to 92%.
Stulak et al. [41] analysed data from 56 patients who
underwent the bipolar radiofrequency (RF) ablation lesions
to both atria using the Cox-Maze III incision map. Results
from this study showed that the use of RF ablation was
associated with significantly less freedom from AF both at
hospital discharge and after 15 months of followup. They
were 5 times more likely to be in AF on followup. However,
the use of RF while performing concomitant surgery may
simplify the procedure, but with a lower chance of treating
AF.
4.5. Minimally Invasive Procedures. The surgical treatment
of atrial fibrillation has evolved further with time and has
become technically simpler and faster with the advent of new
ablative technologies. Complete endoscopic ablation with
microwave energy has been performed with good success and
few complications. Pruitt and colleagues [42] studied fifty
patients with atrial fibrillation (33 paroxysmal and 17 perma-
nent) who underwent thoracoscopic or robotic-assisted oﬀ-
pump epicardial microwave ablation. Those investigations
reported no perioperative death, a mean length of stay of 4
days, and a 79.5% (35 of 44 patients) success rate overall,
with much better cure rates in paroxysmal disease (93.5%)
than in permanent disease (69.2%). In 5 patients (10.0%)
microwave ablation and subsequent electrophysiology inter-
vention failed and a Cox-Maze III operation was performed
to achieve cure or sinus rhythm.
In another study, Beyer and colleagues [43] performed a
multicenter study of 100 patients with atrial fibrillation (39
paroxysmal, 29 persistent, and 32 permanent) who under-
went bilateral minithoracoscopic, video-assisted, pulmonary
vein ablations using bipolar radiofrequency, ganglionic map-
ping and ablation, and LAA resection. The mean operative
time was 253 minutes, and the mean length of stay was 6.5
days. Results showed that there was an 86% overall success
rate (93% paroxysmal, 96% persistent, and 71% permanent),
62% discontinuation of antiarrhythmic drugs, and 65% dis-
continuation of anticoagulation. However, there was a 13%
rate of complication (pacemaker implantation, phrenic nerve
injury, postoperative hemothorax, and transient ischemic
attack) over a mean follow-up time of 13.6 months.
There are many promising innovations using minimal-
access procedures for standalone and concomitant AF. It is
prudent to say that within a few years, surgeons will be
performing a number of surgical ablations with minimal
complexity andmaximum eﬀectiveness, using port-accessed,
video-assisted, and robot-assisted surgical techniques and
specialized navigation instruments.
5. Conclusion
There are three epidemics of cardiovascular disease in the
21st century: atrial fibrillation, congestive heart failure,
and the metabolic syndrome. AF is common in patients
presenting for cardiac surgery. If it is left untreated, it
increases morbidity and mortality. Therefore, one should
consider surgery for AF in those patients.
One of the most significant obstacles facing the
widespread adoption of surgical approaches is the lack of
large controlled studies and trials that evaluate the diﬀerent
techniques and methods for surgical ablation of AF. In
addition, further understanding of the fundamental electro-
physiological mechanism of AF will aid in finding new
approaches and a cure for this arrhythmia. AF must be
targeted quickly because the longer the patient is in AF, the
harder it becomes for him/her to revert back to sinus rhythm,
“AF begets AF.”
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